ArticleStroke2026
Recombinant Irisin Therapy Alters Brain Transcriptome and Protects Against Ischemic Damage in Middle-Aged Rats.
Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIrisin, a myokine cleaved from its precursor FNDC5 (fibronectin type III domain-containing protein 5) following exercise or low-frequency whole-body vibration, regulates energy metabolism and insulin sensitivity. This study examines irisin's therapeutic potential in stroke in rats.
methodsAdult Sprague-Dawley rats of both sexes underwent transient middle cerebral artery occlusion (90 minutes) or sham surgery. After 4.5 hours, they were randomized to receive saline or irisin treatment (0.1, 0.2, and 0.8 μg/g body weight). Infarct volume was quantified 1 day after transient middle cerebral artery occlusion using 2,3,5-triphenyltetrazolium chloride staining. In a subsequent study, reproductively senescent female rats received either saline or 0.2 μg/g body weight irisin at 4.5 hours post-transient middle cerebral artery occlusion, followed by weekly treatments for a month. Sensorimotor and cognitive functions were assessed using the cylinder test and Morris water maze. Ipsilateral cortical tissue was collected from a subset of the reproductive senescence rats following 2 weeks of treatment for RNA sequencing and real-time quantitative polymerase chain reaction analysis.
resultsIrisin (0.2 μg/g) significantly reduced infarct volume by 50% in females and 36% in males compared with their respective saline groups. In reproductive senescence females, irisin treatment for a month improved contralateral limb use by day 7 and enhanced spatial learning in the Morris water maze, reducing latency to find the hidden platform on the fourth day of testing (16.5 sec versus saline;
conclusionsPost-transient middle cerebral artery occlusionirisin therapy modulates the transcriptome, enhancing motor and cognitive function while protecting against ischemic brain damage in middle-aged female rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.